IP Library Granted Patent US 8,741,299
Granted Patent B2
US 8,741,299 · App. 13/528,350 · Granted Jun 3, 2014

Method for treating pathologies associated with hypoxia using MIF inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,741,299
App. No.
13/528,350
Granted
Jun 3, 2014
Kind
B2
Abstract

Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.

Claims (11)

1. A method for treating a disorder associated with hypoxia in a subject comprising administering to the subject an amount of a small molecule macrophage migration inhibitory factor (MIF) inhibitor effective to treat pulmonary hypertension associated with hypoxia.

2. The method of claim 1 , wherein the disorder is hypoxia-induced pulmonary hypertension.

3. The method of claim 1 , wherein the subject has chronic obstructive pulmonary disease or has interstitial lung disease.

4. The method of claim 3 , wherein the subject has chronic obstructive pulmonary disease.

5. The method of claim 3 , wherein the subject has interstitial lung disease.

6. The method of claim 1 , wherein the subject has previously been diagnosed as having pulmonary hypertension.

7. The method of claim 1 , wherein the subject has hypoxia-induced right ventricular hypertrophy.

8. The method of claim 1 , wherein the subject has hypoxia-induced pulmonary vascular remodeling.

9. The method of claim 1 , wherein the MIF inhibitor is administered inhalationally.

10. The method of claim 1 , wherein the small molecule MIF inhibitor has the structure:

11. A method for treating hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling in a subject comprising administering to the subject an amount of a small molecule macrophage migration inhibitory factor (MIF) inhibitor effective to treat hypoxia-induced right ventricular hypertrophy or effective to treat hypoxia-induced pulmonary vascular remodeling.

Assignments (2)
CHANGE OF NAME Recorded Aug 20, 2019
From: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
To: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Reel/Frame 050102/0485 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2012
From: MILLER, EDMUND; AL-ABED, YOUSEF; ZHANG, YINZHONG; CHENG, KAI FAN
To: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 028620/0509 →